Multicenter phase 2 study of first-line pembrolizumab for advanced Merkel cell carcinoma
Prof. Paul Nghiem
A multicenter phase 2 study in the USA found that first-line pembrolizumab for advanced Merkel cell carcinoma resulted in durable progression-free and overall survival in a proportion of patients. After initial tumor progression or relapse following response, some patients receiving salvage therapies survived.
